Ces radiol. 2008, 62(3):244-253
Bronchogenic carcinoma: magnetic resonance imaging of the thorax with gadofosveset applicationOriginal article
- 1 Radiodiagnostická klinika LF UK a FN, Plzeň
- 2 Oddělení onkologie a radioterapie FN, Plzeň
Aim: To evaluate and optimize the feasible imaging protocol used in thoracic magnetic resonance imaging of bronchogenic carcinoma (BrCa) including application of blood-pool contrast agent gadofosveset.
Material and method. 18 patients underwent thoracic magnetic resonance within 18 months (7 females, 11 males, mean age 63.3 y) There were four small-cell BrCa in clinical stage of extensive disease and 14 non-small-cell BrCa in clinical stage IIIB or IV. Imaging protocol contained T2 w. HASTE in three orthogonal planes; T2 w. STIR in axial plane before application of gadofosveset. Gadofosveset was injected during dynamic acquisition of 3D FLASH VIBE sequence with six cycles of data acquisition including first non-enhanced. The images of pulmonary vasculature were performed in steady-state of intravascular distribution of gadofosveset. The image quality optimal timing and orientation of sequences were evaluated.
Results: The valuable examination was performed in all 18 cases. Optimal image quality of the tumorous tissue was reached in T2 STIR sequence and during dynamic data acquisition after application of gadofosveset. The pulmonary vasculature and also the vascularity of the tumorous tissue were enabled to be assessed when we used the steady-state ceMRA imaging sequence.
Conclusion: Using optimized imaging protocol, the magnetic resonance of the chest is able to become an alternative imaging method to the computed tomography or PET/CT.
Keywords: bronchogenic carcinoma, magnetic resonance imaging, gadofosveset
Accepted: July 24, 2008; Published: September 1, 2008 Show citation
References
- Novák K. Současná incidence a léčba bronchogenního karcinomu v Československu. Cas Lek Cesk 1990; 129: 172-174.
- Plathow C, Aschoff P, Lichy MP, Eschmann S, Hehr T, Brink I, Claussen CD, Pfannenberg C, Schlemmer HP. Positron emission tomography/computed tomography and whole-body magnetic resonance imaging in staging of advanced nonsmall cell lung cancer-initial results. Invest Radiol 2008; 43: 290-297.
Go to original source... 
Go to PubMed... - Nomori H, Mori T, Ikeda K, Kawanaka K, Shiraishi S, Katahira K, Yamashita Y. Diffusion-weighted magnetic resonance imaging can be used in place of positron emission tomography for N staging of non-small cell lung cancer with fewer false-positive results. J Thorac Cardiovasc Surg 2008; 135: 816-822. Go to original source... Go to PubMed...
- Kreuzberg B, Ferda J. Celotělové vyšetření magnetickou rezonancí. Ces Radiol 2007; 61: 351-363.
- Jena A, Taneja S, Talwar V, Sharma JB. Magnetic resonance (MR) patterns of brain metastasis in lung cancer patients: correlation of imaging findings with symptom. J Thorac Oncol 2008; 3: 140-144. Go to original source... Go to PubMed...
- Imamura F, Kuriyama K, Seto T, Hasegawa Y, Nakayama T, Nakamura S, Horai T. Detection of bone marrow metastases of small cell lung cancer with magnetic resonance imaging: early diagnosis before destruction of osseous structure and implications for staging. Lung Cancer 2000; 27: 189-197. Go to original source... Go to PubMed...
- Mochizuki T, Tsukamoto E, Kuge Y, et al. FDG uptake and glukose transporter subtype expressions in experimental tumor and inflammation models. J Nucl Med 2001; 28, 1551-1555.
- Kubota R, Yamada S, Kubota K Ishiwata K Tamahashi N, Ido T. Intratumoral distribution of fluorine-18-fluorodeoxyglucose in vivo: high accumulation in macrophages and granulation tissues studied by microautoradiography. J Nucl Med 1992; 33: 1972-1980.
- Zhou X, Bao H, Al-Hashem R, Ji H, Albert M, Wong KK, Sun Y. Magnetic resonance imaging of the response of a mouse model of non-small cell lung cancer to tyrosine kinase inhibitor treatment. Comp Med 2008; 58: 276-281.
- Rosen Y, Ramniceanu G, Margalit R, Grobgeld D, Eilam R, Degani H, Furman-Haran E. Vascular perfusion of human lung cancer in a rat orthotopic model using dynamic contrast-enhanced magnetic resonance imaging. Int J Cancer 2006; 119: 365-372. Go to original source... Go to PubMed...
- Henness S, Keating GM. Gadofosveset. Drugs 2006; 66: 851-857. Go to original source... Go to PubMed...
- Goyen M. Gadofosveset-enhanced magnetic resonance angiography. Vasc Health Risk Manag 2008; 4: 1-9. Go to original source...
- Tyeklar Z, Dunham SU, Midelfort K, Scott DM, Sajiki H, Ong K, Lauffer RB, Caravan P, McMurry TJ. Structural, kinetic, and thermodynamic characterization of the interconverting isomers of MS-325, a gadolinium(III)-based magnetic resonance angiography contrast agent. Inorg Chem 2007; 46: 6621-6631. Go to original source... Go to PubMed...
- Caravan P, Parigi G, Chasse JM, Cloutier NJ, Ellison JJ, Lauffer RB, Luchinat C, McDermid SA, Spiller M, McMurry TJ. Albumin binding, relaxivity, and water exchange kinetics of the diastereoisomers of MS-325, a gadolinium(III)-based magnetic resonance angiography contrast agent. Inorg Chem 2007; 46: 6632-6639. Go to original source... Go to PubMed...
- Goyen M, Edelman M, Perreault P, O'Riordan E, Bertoni H, Taylor J, Siragusa D, Sharafuddin M, Mohler ER 3rd, Breger R, Yucel EK, Shamsi K, Weisskoff RM. MR angiography of aortoiliac occlusive disease: a phase III study of the safety and effectiveness of the blood-pool contrast agent MS-325. Radiology 2005; 236: 825-833. Go to original source... Go to PubMed...
This is an open access article distributed under the terms of the Creative Commons Attribution 4.0 International License (CC BY 4.0), which permits use, distribution, and reproduction in any medium, provided the original publication is properly cited. No use, distribution or reproduction is permitted which does not comply with these terms.